Posaconazole exposure in critically ill ICU patients: a need for action

[21] Chakrabarti A(2022)Suboptimal plasma concentrations with posaconazole suspension as prophylaxis in critically ill COVID-19 patients at risk of Covid-associated pulmonary aspergillosis J Clin Pharm Ther 315 2957-1376

[22] Chen SCA(2016)The third international consensus definitions for sepsis and septic shock (Sepsis-3) JAMA 270 1367-1241

[23] Colombo AL(1993)A new Simplified Acute Physiology Score (SAPS II) based on a European/North American multicenter study JAMA 71 155-726

[24] Hoenigl M(2020)Revision and update of the consensus definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer and the Mycoses Study Group Education and Research Consortium Clin Infect Dis 18 1234-660

[25] Patterson TF(2018)Utility of posaconazole therapeutic drug monitoring and assessment of plasma concentration threshold for effective prophylaxis of invasive fungal infections: a meta-analysis with trial sequential analysis BMC Infect Dis 76 718-444

[26] Thompson GR(2021)Pharmacokinetics and target attainment of intravenous posaconazole in critically ill patients during extracorporeal membrane oxygenation J Antimicrob Chemother 71 656-941

[27] Denning DW(2015)Phase 3 pharmacokinetics and safety study of a posaconazole tablet formulation in patients at risk for invasive fungal disease J Antimicrob Chemother 65 433-3301

[28] Fishman JA(2018)Pharmacokinetics of intravenous posaconazole in critically ill patients Antimicrob Agents Chemother 102 931-1212

[29] Hadley S(2022)Exposure to intravenous posaconazole in critically ill patients with influenza: a pharmacokinetic analysis of the POSA-FLU study Mycoses 11 3291-undefined

[30] Herbrecht R(2017)ECIL-6 guidelines for the treatment of invasive candidiasis, aspergillosis and mucormycosis in leukemia and hematopoietic stem cell transplant patients Haematologica 99 1207-undefined

[21] Chakrabarti A(2022)Suboptimal plasma concentrations with posaconazole suspension as prophylaxis in critically ill COVID-19 patients at risk of Covid-associated pulmonary aspergillosis J Clin Pharm Ther 315 2957-1376

[22] Chen SCA(2016)The third international consensus definitions for sepsis and septic shock (Sepsis-3) JAMA 270 1367-1241

[23] Colombo AL(1993)A new Simplified Acute Physiology Score (SAPS II) based on a European/North American multicenter study JAMA 71 155-726

[24] Hoenigl M(2020)Revision and update of the consensus definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer and the Mycoses Study Group Education and Research Consortium Clin Infect Dis 18 1234-660

[25] Patterson TF(2018)Utility of posaconazole therapeutic drug monitoring and assessment of plasma concentration threshold for effective prophylaxis of invasive fungal infections: a meta-analysis with trial sequential analysis BMC Infect Dis 76 718-444

[26] Thompson GR(2021)Pharmacokinetics and target attainment of intravenous posaconazole in critically ill patients during extracorporeal membrane oxygenation J Antimicrob Chemother 71 656-941

[27] Denning DW(2015)Phase 3 pharmacokinetics and safety study of a posaconazole tablet formulation in patients at risk for invasive fungal disease J Antimicrob Chemother 65 433-3301

[28] Fishman JA(2018)Pharmacokinetics of intravenous posaconazole in critically ill patients Antimicrob Agents Chemother 102 931-1212

[29] Hadley S(2022)Exposure to intravenous posaconazole in critically ill patients with influenza: a pharmacokinetic analysis of the POSA-FLU study Mycoses 11 3291-undefined

[30] Herbrecht R(2017)ECIL-6 guidelines for the treatment of invasive candidiasis, aspergillosis and mucormycosis in leukemia and hematopoietic stem cell transplant patients Haematologica 99 1207-undefined